S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MTNB Matinas Biopharma Holdings Inc

0.1878

0.0021 (1.13%)

02 May 2024 - Closed

Delayed by 15 minutes

Matinas Biopharma Q3 2021 Earnings Preview

To read the full story on Seeking Alpha, click here.

Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Matinas Biopharma Charts.

Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Matinas Biopharma Charts.

Matinas Biopharma Holdings Inc News

In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Tuesday 30 April 2024 (2 days ago) • GlobeNewswire Inc.

Matinas BioPharma Prices $10 Million Registered Direct Offering
Wednesday 3 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Thursday 28 March 2024 (1 month ago) • GlobeNewswire Inc.

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Saturday 23 March 2024 (1 month ago) • GlobeNewswire Inc.

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Friday 22 March 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 27 February 2024 (2 months ago) • Edgar (US Regulatory)

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 20 February 2024 (2 months ago) • Edgar (US Regulatory)

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Tuesday 20 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 9 January 2024 (4 months ago) • Edgar (US Regulatory)

Matinas BioPharma to Present at Biotech Showcase 2024
Wednesday 3 January 2024 (4 months ago) • GlobeNewswire Inc.

More Matinas Biopharma Holdings Inc News Articles

Australian SE All Ordina...

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions